NTRA Price Prediction Next Week
Technical Analysis: NTRA's current price at $176 shows a bullish trend with strong momentum. RSI-14 at 54.16 indicates neutral territory but with upward potential. The MACD line (1.63) above signal line suggests positive momentum, though the negative histogram (-0.49) indicates some short-term weakness.
Price Levels:
- Fibonacci resistance levels: R1: $178.01, R2: $181.41, R3: $186.92
- Fibonacci support levels: S1: $166.98, S2: $163.58, S3: $158.06
- Current price ($176) is trading above all major SMAs, indicating strong uptrend
News Impact:
- Positive institutional confidence shown by Druckenmiller's Duquesne Family Office maintaining NTRA as their largest holding
- Recent insider sales by executives show some profit-taking but not concerning given the small percentage of their holdings
Next Week Price Prediction: Based on technical indicators and Fibonacci levels:
- Target price: $181-183
- Stop loss: $166.98 (S1 level)
- Trading recommendation: BUY with tight stop loss
Rationale:
- Price momentum remains positive with strong support from moving averages
- Bollinger Band position (0.58) suggests room for upward movement
- First resistance at $178.01 likely to be tested early in the week
- If broken, next target at $181.41 becomes achievable
NTRA Similar Chart Price Prediction
The price of NTRA is predicted to go up 8.37%, based on the high correlation periods with ULS. The similarity of these two price pattern on the periods is 91.58%.
NTRA
ULS
Up: 8.37%Similarity: 91.58%
NTRA Revenue Forecast
NTRA EPS Forecast
NTRA FAQs
What is bull’s view on NTRA?
What is bear's view on NTRA?
What is NTRA revenue forecast for next quarter？
NTRA Analyst's Forecast
Luke Sergott
Barclays
Buy
2025-01-23
Price Target
$200
Upside
+16.4%
Barclays analyst Luke Sergott initiated coverage of Natera with an Overweight rating and $200 price target. The firm started the liquid biopsy space with Overweight ratings on three names. The technology is "breaking out" with broader adoption across key markets, the analyst tells investors in a research note. Barclays expects volumes to continue to ramp as companies publish data, expand menus across indications and markets, and payers increase coverage across lives as this technology continues to show its utility. "It is too early to pick a winner given how early we are in adoption, so in the meantime we believe that a rising tide will lift all boats," contends the firm. Barclays sees a "very long runway" from the underpenetrated markets as coverage unlocks selling prices and additional indications unlock more addressable markets.
Subbu Nambi
Guggenheim
Strong Buy
2025-01-17
Price Target
$170 → $200
Upside
+26.29%
Eve Burstein
Bernstein
Buy
2025-01-10
Price Target
$160 → $200
Upside
+14.29%
